Dr. Argiles Discusses the Role of Immunotherapy in CRC

Guillem Argiles, MD
Published: Thursday, Sep 07, 2017



Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer (CRC).

There is an important role for immunotherapy in the hyper-mutant population of patients with CRC, says Argiles.

As of now, pembrolizumab (Keytruda) is approved in the United States for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors.
 
SELECTED
LANGUAGE


Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer (CRC).

There is an important role for immunotherapy in the hyper-mutant population of patients with CRC, says Argiles.

As of now, pembrolizumab (Keytruda) is approved in the United States for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x